Skip to main content
. 2023 Nov 22;11:1240392. doi: 10.3389/fpubh.2023.1240392

Figure 1.

Figure 1

Drug-resistance prevalence among UPEC isolates from patients with reUTI and peUTI. Ampicillin (AMP), piperacillin (PRL), carbenicillin (CAR), mecilanam (MEL), amox-clavulanic acid (AMC), piperacillin-tazobactam (TZP), cefazolin (KZ), cephalothin (KF), cefamandol (MA), cefepime (FEP), cefoperazone (CFP), cefoxitin (FOX), ceftriaxone (CRO), ceftazidime (CAZ), furoxime (CXM), meropenem (MEM), nitrofurantoin (F), aztreonam (ATM), gentamicin (CN), amikacin (KA), kanamycin (K), tobramycin (TOB), streptomycin (S), tetracycline (TE), ciprofloxacin (CIP), norfloxacin (NOR), trimethoprim-sulfamethoxazole (SXT), nalidixic acid (NA), sulfonamides (S3), trimetroprim (W), chloramphenicol (C), fosfomycin (FOS), fosfomycin trometramol (FOT). The dotted line marks the 20% resistance threshold. Fisher’s exact test was performed, *p < 0.05.